Video

Dr. Badani on Determining Which Patients With RCC Will Receive Robotic Surgery

Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses how to determine which patient with renal cell carcinoma (RCC) will benefit from robotic surgery.

Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses how to determine which patient with renal cell carcinoma (RCC) will benefit from robotic surgery.

Who receives robotic surgery for RCC remains in the hands of the physician, explains Badani. Doing an open partial nephrectomy, a laparoscopic partial nephrectomy, or a robotic partial nephrectomy are all good options when treating a patient.

As a physician’s experience matures with robotic surgery, they will start to see the advantages of it but should offer what they feel comfortable with, states Badani. Most kidney operations done in the United States are not done using robotics.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD